Related Experiment Videos
[Adjuvant tamoxifen duration: more large-scale randomized evidence is needed]
1Department of Breast Surgery, National Kyushu Cancer Centre, Fukuoka, Japan.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|August 1, 1997
Summary
Adjuvant tamoxifen provides survival benefits for early breast cancer patients. The ATLAS trial investigates if extending tamoxifen treatment by five years offers further advantages or risks, guiding optimal duration for improved outcomes.
Area of Science:
- Oncology
- Clinical Trials
- Evidence-Based Medicine
Context:
- Adjuvant tamoxifen therapy offers moderate long-term survival benefits in early breast cancer.
- Optimal duration of tamoxifen treatment remains uncertain, with clinical equipoise regarding continuing or stopping therapy after initial years.
Purpose:
- To reliably assess the benefits and risks of prolonging tamoxifen duration by an additional five years.
- To provide evidence for optimal adjuvant tamoxifen treatment duration in early breast cancer management.
Summary:
- The ATLAS trial is a large international randomized study.
- It evaluates extending tamoxifen therapy by five years in women with early breast cancer who have already received initial treatment.
- The study aims to resolve uncertainty about the best treatment duration.
Impact:
- Findings will inform clinical practice for hundreds of thousands of women worldwide.
- This research has the potential to further reduce breast cancer mortality rates.
- The study addresses a critical question in breast cancer management, impacting patient outcomes.